HC Wainwright & Co. Reiterates Buy on BioCardia, Maintains $4 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. has reiterated its Buy rating on BioCardia (NASDAQ:BCDA) and maintained a $4 price target, as stated by analyst Joseph Pantginis.
May 29, 2024 | 5:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
HC Wainwright & Co. has reiterated its Buy rating on BioCardia and maintained a $4 price target, indicating continued confidence in the company's prospects.
The reiteration of a Buy rating and maintenance of a $4 price target by a reputable analyst firm like HC Wainwright & Co. is likely to positively influence investor sentiment and potentially drive short-term price appreciation for BioCardia.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100